LATEST UPDATES » Vol 22, No 12, December 2018 – The story of WeDoctor - The medical service system for tomorrow       » World's first unmanned clinic in China       » International outcry over world's first gene-edited babies born in China       » More HIV-positive foreigners enter China       » Pain-free childbirth to be promoted in China       » The past, present and future of life science      
United States dominates biosimilars market
Although the US dominates the biosimilars market, Brazil and South Korea are gaining a foothold

Biosimilars are becoming increasingly popular with pharmaceutical companies, however, knowing which markets have been saturated with biosimilars and which are open, remains an important consideration for pharma companies, observes GlobalData, a data and analytics company.

Lisa Marris, healthcare analyst at GlobalData commented, “The deal activity can provide a useful indication of which biosimilar drugs are in development. The recent strategic alliance deals show the potential of bringing these biosimilar monoclonal antibodies to market for therapy areas such as cancer or autoimmune diseases.”

Emerging markets, such as Brazil and South Korea, have been involved in a growing number of deals for the development or commercialization of biosimilars gaining a foothold for these countries in the future of the biosimilar market.

With the exception of etanercept, the top six biosimilar drugs over the past five years are monoclonal antibodies which are all used to treat either autoimmune diseases or cancer. The rituximab biosimilar is the top drug in terms of the highest deal value, with adalimumab biosimilar involved in the highest number of deals. Three of the top six biosimilars were involved in the highest valued strategic alliance deals in the past five years. The $275M co-development agreement between Epirus and Orygen Biotecnologia in 2013 allowed Epirus to market Orygen Biotecnologia’s infliximab, rituximab, and trastuzumab biosimilars in Brazil.

Sanofi’s co-development with JHL Biotech in 2016 was the second most valuable deal and involves the most drugs of any other deal in the past five years. Sanofi acquired the rights to the rituximab biosimilar, as well as its pipeline adalimumab, bevacizumab and trastuzumab biosimilars. JHL Biotech is to lead the development, registration, and manufacturing activities while Sanofi will lead commercialization in China.

The countries with the highest deal values and highest number of deals in the past five years, reveals that the US continues to dominate biosimilar activity with the highest total deal value and highest percentage of deals for an individual country.

The EU has a larger proportion of deals compared to the US and these are predominately made up of Germany and the UK. Brazil and South Korea are also active in the biosimilar market.

The partnership between Epirus and Orygen Biotecnologia was Brazil’s most notable deal. The South Korean company Celltrion entered into a co-marketing agreement with Teva Pharmaceutical Industries to commercialize its pipeline biosimilars for rituximab and trastuzumab, in the US and Canada.

Marris added, ‘‘This shows that, although the US is likely to continue to dominate the future of biosimilar activity, the emerging markets are beginning to get a foothold in the biosimilar marketplace.’’

Click here for the complete issue.

news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management - Technologies for biotech and pharmaceutical industries
Regenerative technology - Meat of the future
Doctor Robot - The digital healthcare revolution
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy